Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oral bradykinin B2 receptor antagonists. These antagonists are designed to treat hereditary angioedema (HAE) and other conditions mediated by the bradykinin B2 receptor. The company aims to provide an alternative to the currently available injected therapies, offering patients a more convenient oral treatment option. Pharvaris operates in the biopharmaceutical market, targeting patients suffering from rare and debilitating conditions. The company's business model revolves around the research, development, and eventual commercialization of its proprietary oral therapies. Revenue generation is anticipated through the successful development and approval of these therapies, followed by their marketing and sales. Pharvaris serves a niche market of patients with specific medical needs, focusing on innovative solutions that improve patient choice and quality of life.

Keywords: bradykinin B2 receptor, hereditary angioedema, oral therapy, clinical-stage, biopharmaceutical, novel antagonists, patient choice, rare diseases, alternative treatment, drug development.